The embolic protection devices market size was valued at USD 0.3 Billion in 2022. The embolic protection devices industry is projected to grow from USD 0.33 Billion in 2023 to USD 0.62 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.40% during the forecast period (2023 - 2032).
The expansion in demand for minimally invasive procedures, the rise in research and development activities associated with embolic protection devices, and the advancement in medical technology are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
January 2023, Cardinal Health Inc., a renowned leader in medical products and healthcare services, formed a strategic partnership with Palantir, an acclaimed technology company providing data integration and analysis. This noteworthy alliance is one of its kind as far as supply chain management in the health sector.
In January 2022, Cardiovascular Systems Inc. recalled the WIRION Embolic Protection Device due to instances of filter breakage during retrieval.
In May 2021, Emboline raised $55m in Series D funding to develop an embolic protection device designed for a comprehensive defense against emboli through trans-catheter treatments by effectively capturing and eliminating debris.
Contego Medical LLC, a leading pioneer in cardiovascular devices, achieved an important milestone when it received the highly sought-after CE Mark approval for its cutting-edge invention, Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System). This announcement represents a significant progression within interventional cardiology. The combination of carotid stent and post-dilation balloon features state-of-the-art embolic protection mechanisms available on the Neuroguard IEP System that provide different ways of addressing this problem simultaneously.
In March 2021, Innovative Cardiovascular Solutions (ICS), LLC made another remarkable stride toward its goal of being at the forefront of research regarding embolic protection during structural heart and vascular interventions globally. The company has recently reported completing initial European clinical cases for advancing patient care with a new iteration of its groundbreaking EMBLOK™ Embolic Protection System.
Market CAGR for embolic protection devices is driven by the rising prevalence of cardiovascular disorders and neurovascular diseases among people, technological advancements in embolic protection devices, and increasing product launches by key market players in the diagnostic field are some of the prominent factors driving the market revenue growth. In addition, advancing demand for minimally invasive surgeries and growing government initiatives in research and development activities for pre-diagnostics contribute to revenue growth of the embolic protection devices market. Embolic Protection Devices (EPDs) capture blood and luminal debris inside the Saphenous Vein Grafts (SVG), preventing distal embolization during stenting. The most effective evidence-based method for periprocedural Myocardial Infarction and Major Adverse Cardiovascular Events reduction during SVG treatments is to use EPDs. The American College of Cardiology recommends using EPDS where it is physically possible.
Additionally, increasing product launches and investment by key market players and initiatives by federal government agencies in the diagnostic field contribute to market revenue growth. For instance, in June 2022, Conformal Medical, Inc., a medical device firm manufacturing next-generation LAAO technology, announced the beginning of the CONFORM pivotal trial, with the first patients enrolled at two U.S. sites. The Investigational Product Exemption (IDE) research will compare the safety and efficacy of the firm's CLAAS System to commercially marketed LAAO devices to support FDA pre-market approval.
Technological improvements and breakthroughs in embolic protection devices are expected to boost the business outlook over the next ten years. Distal occlusion devices, distal filter devices, and proximal occlusion/flow-reversal devices, among other innovations, are intended to avoid embolic debris during endovascular operations. For instance, Medtronic's Mo. Ma Ultra proximal cerebral protection device uses a double-occlusion balloon system to guarantee proximal embolic protection before passing a carotid lesion. Continuous R&D targeted at enhancing these devices' efficacy, safety, and ease of use will contribute to their increased acceptance.
Government bodies, Non-Governmental Organizations (NGOs) and educational institutes across various regions are spreading awareness about cardiovascular and neurovascular diseases and their possible treatment by launching awareness programs driving the embolic protection devices market revenue.
The embolic protection devices market segmentation, based on type, includes distal filter devices, distal occlusion devices, and proximal occlusion devices. The distal filter device segment dominated the market, accounting for 35% of market revenue (0.12 Billion). In developing economies, category growth is driven by ease of use, lack of interference with lesion visualization, and availability in various specifications. However, the distal occlusion device is the fastest-growing category owing to rising regulatory approvals by federal government agencies and their initiatives to develop these devices.
The embolic protection devices market segmentation, based on material, includes nitinol and polyurethane. The nitinol category generated the most income (70.4%) owing to its unique properties and versatility in the design of embolic protection devices. However, polyurethane is the fastest-growing category due to its unique combination of properties such as mechanical strength, flexibility, biocompatibility, and low thrombogenicity.
The embolic protection devices market segmentation, based on usage, includes disposable devices and re-usable devices. The disposable device category generated the most income due to the rising prevalence of chronic illnesses, such as neurological, cardiovascular, infectious, and urological disorders. However, polyurethane is the fastest-growing category due to its cost-effectiveness.
The embolic protection devices market segmentation, based on application, includes cardiovascular diseases, {coronary artery diseases, trans cather aortic valve replacement, saphenous vein graft diseases}, neurovascular diseases, and peripheral vascular diseases. The cardiovascular diseases category generated the most income owing to rising cases of this disease. However, peripheral vascular diseases are the fastest-growing category due to the growing vogue of minimally invasive procedures, which offer various advantages over conventional methods, such as reduced complications, quicker recovery times, and minimal invasiveness.
The embolic protection devices market segmentation, based on end-user, includes hospitals & clinics, ambulatory surgical centers, and specialty centers. The hospitals & clinics category generated the most income owing to the high prevalence of highly qualified healthcare professionals and staff. However, specialty centers are the fastest-growing category due to the growing emphasis on patient safety, the adoption of technology-based solutions, and favorable reimbursement policies for endovascular procedures in specialty centers.
Figure 1 Embolic Protection Devices Market, by End-User, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Embolic Protection Devices Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American embolic protection devices market will dominate this market owing to increasing investments by the government, and the high rate of acceptance of newly developed items among end-users will boost the market growth in this region. Further, the German embolic protection devices market held the largest market share, and the UK embolic protection devices market was the fastest-growing market in the European region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 EMBOLIC PROTECTION DEVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's embolic protection devices market accounts for the second-largest market share due to the partnerships of leading companies and technological advancements and several in this region. Further, the German embolic protection devices market held the largest market share, and the UK embolic protection devices market was the fastest-growing market in the European region.
The Asia-Pacific embolic protection devices market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to rising clinical trials in this region. Moreover, China’s embolic protection devices market held the largest market share, and the Indian embolic protection devices market was the fastest-growing market in the Asia-Pacific region.
Embolic Protection Devices Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the embolic protection devices market grow even more. Market participants are also undertaking several strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the embolic protection devices industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the embolic protection devices industry to benefit clients and increase the market sector. Major players in the embolic protection devices market, including Siemens Healthcare GmbH, Hologic, Inc., Sinduri Biotec., SEKISUI MEDICAL CO., LTD., NIPRO, Danaher, and others, are attempting to increase market demand by investing in research and development operations.
Abbott Laboratories discovers, creates, manufactures and sells a diversified range of healthcare products, such as branded generic pharmaceuticals, diagnostic systems and tests, and pediatric and adult nutritional products. The firm also offers various medical devices, including heart failure, electrophysiology, vascular and structural heart devices, rhythm management, and neuromodulation devices. The firm also delivers minerals and nutrition products and dietary supplements. It has research and development facilities across the world. In September 2021, Abbott acquired Walk Vascular, a commercial-stage medical device company that develops minimally invasive mechanical aspiration thrombectomy systems to remove peripheral blood clots.
Cardiovascular Systems Inc, a subsidiary of Abbott Laboratories, is a medical device firm that develops and commercializes products for treating peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy systems, coronary orbital atherectomy systems, crowns, and accessories. Its peripheral artery disease system is a percutaneous orbital atherectomy system used to treat OAS atherosclerotic disease in peripheral arteries. CSI offers accessories such as guide wires, lubricants, infusion pumps and ancillary products. It has developed orbital atherectomy systems technology for peripheral and coronary commercial applications. The company serves patients suffering from peripheral arterial disease and coronary artery diseases. In November 2021, Cardiovascular Systems, Inc. launched a voluntary recall of the WIRION Embolic Protection System.
Key Companies in the Embolic Protection Devices market include
Embolic Protection Devices Industry Developments
October 2021 The Neuroguard IEP three-in-one Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System) received CE Mark clearance from Contego Medical Inc., a cardiovascular device developer. The Neuroguard IEP System is a patented system with a revolutionary next-generation nitinol stent, a pre-positioned post-dilation balloon, and an integrated microembolic filter with 40 m pores.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)